Publicly traded company LIXTE Biotechnology will allocate up to 25% of the company's financial reserves to cryptocurrency, pending approval.
BlockBeats News, August 13th, Clinical-stage pharmaceutical company LIXTE Biotechnology Holdings, Inc. (Nasdaq codes: LIXT and LIXTW) announced today that its board of directors has approved a strategic capital allocation plan that will incorporate cryptocurrency into the company's financial reserves. The board has approved allocating up to 25% of the company's financial reserves to cryptocurrency, including Bitcoin and other digital assets as deemed appropriate on a case-by-case basis.
The timing and scale of any such transactions will depend on market conditions at the time and other strategic considerations. LIXTE will continue to closely monitor developments in the digital asset space and retain flexibility to adjust its holdings. The company plans to have all cryptocurrency assets held by fully regulated and compliant custodians. All future transactions will strictly adhere to relevant financial, legal, and auditing regulations to ensure transparency, security, and full regulatory compliance.
Também poderá gostar de
Em alta
Últimas notícias cripto
Whale "pension-usdt.eth" ontem viu sua posição ETH longa cair abaixo do preço médio, com um tamanho de posição atingindo US$ 56 milhões.
Dark Pool DEX HumidiFi lança ICO, líder em volume de negociação entre os DEXs do ecossistema Solana
O negociante de «Bankrupt» James Wynn abriu uma nova posição de 40x leverage BTC long. Na semana passada, ele previu que o BTC cairia para US $ 67,000 dentro da semana.
Protocolo DeFi Zoo Finance anunciou a conclusão de uma rodada estratégica de levantamento de fundos de US$ 8 milhões.
Jiangnan Technology Teams Up com SynVista para lançar AI Green Mining Platform
Apoio ao cliente:@weikecs
Cooperação empresarial:@weikecs
Trading quant. e criação de mercados:[email protected]
Serviços VIP:[email protected]